What it is
Bioglutide is a compound being developed by Biomed Industries. The company says it is a pill taken once a day. The company says it acts on four receptors: IGF-1, GLP-1, GIP, and glucagon. No structure has ever been made public. It is not confirmed to be a peptide. No formula, sequence, or CAS number has been released. Other names: NA-931.
What researchers study it for
- Body weight in adults with obesity (company claim)
- Blood sugar in type 2 diabetes (company claim)
- Pairing with tirzepatide (planned trial)
What the studies found
No studies on bioglutide have been published in PubMed. No results have been posted for any of its trials. No claim about what it does can be checked at this time.
How much research exists
Three trials are listed on ClinicalTrials.gov, all run by the company. These are NCT06615700 (phase 1, 74 people, listed as completed), NCT06564753 (phase 2, 126 people, listed as completed), and NCT06732245 (phase 2 with tirzepatide, not yet recruiting). No results are posted for any of them. The phase 1 trial was registered about 5 months after it started. The phase 2 entry rules are almost the same, word for word, as an earlier trial for a different company's drug, VK2735. No lab or animal data has been published.
Facts
- Formula: not released
- Weight: not released
- CAS number: none found
- Sequence: not released
- Time in the blood: no published data
- Storage: no published data
Legal status
Not approved by the FDA or any other agency. No confirmed structure exists, so any product sold as bioglutide or NA-931 cannot be checked against the company's compound.
For research use only. Not for human use. Nothing here is medical advice.